5 research outputs found
The identifiability of patients with carcinogenic somatic mutation of Junus kinase-2 (V617FJAK2) within the framework of programs of dispensary and preventive examinations
No full textΠ’Π΅ΠΊΡΡ ΡΡΠ°ΡΡΠΈ Π½Π΅ ΠΏΡΠ±Π»ΠΈΠΊΡΠ΅ΡΡΡ Π² ΠΎΡΠΊΡΡΡΠΎΠΌ Π΄ΠΎΡΡΡΠΏΠ΅ Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠΈ Ρ ΠΏΠΎΠ»ΠΈΡΠΈΠΊΠΎΠΉ ΠΆΡΡΠ½Π°Π»Π°.The article presents results of identification of somatic mutation in in gene Junus kinase-2 (V617F JAK2) in blood samples of persons included in program of dispensarization of adult population and periodic preventive examinations of workers of railroad transport. The technology of allele-specific polymerase chain reaction in real-time in pooled trials from blood samples received by clinical diagnostic laboratory for hematological analysis was developed with purpose of carrying out study. The results of testing among 986persons aged from 45 to 90 years (median - 69 years) permitted to establish 0.7% of patients (3 females and 4 males) with mutation V617F JAK2. The high thrombogenic potential of mutation V617F JAK2 and its involvement into pathogenesis of chronic myeloid tumors makes appropriate to include test on its detection into menu of laboratory analyses of program of dispensarization of population
The identifiability of patients with carcinogenic somatic mutation of Junus kinase-2 (V617FJAK2) within the framework of programs of dispensary and preventive examinations
No full textΠ’Π΅ΠΊΡΡ ΡΡΠ°ΡΡΠΈ Π½Π΅ ΠΏΡΠ±Π»ΠΈΠΊΡΠ΅ΡΡΡ Π² ΠΎΡΠΊΡΡΡΠΎΠΌ Π΄ΠΎΡΡΡΠΏΠ΅ Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠΈ Ρ ΠΏΠΎΠ»ΠΈΡΠΈΠΊΠΎΠΉ ΠΆΡΡΠ½Π°Π»Π°.The article presents results of identification of somatic mutation in in gene Junus kinase-2 (V617F JAK2) in blood samples of persons included in program of dispensarization of adult population and periodic preventive examinations of workers of railroad transport. The technology of allele-specific polymerase chain reaction in real-time in pooled trials from blood samples received by clinical diagnostic laboratory for hematological analysis was developed with purpose of carrying out study. The results of testing among 986persons aged from 45 to 90 years (median - 69 years) permitted to establish 0.7% of patients (3 females and 4 males) with mutation V617F JAK2. The high thrombogenic potential of mutation V617F JAK2 and its involvement into pathogenesis of chronic myeloid tumors makes appropriate to include test on its detection into menu of laboratory analyses of program of dispensarization of population
Prevalence of the jak2 v617f mutation in some cohorts of the central Siberia (Krasnoyarsk region) population
No full text
